Abstract
During aging skeletal muscle shows an accumulation of oxidative damage as well as intramyocellular lipid droplets (IMLDs). However, although the impact of these modifications on muscle tissue physiology is well established, the direct effectors critical for their occurrence are poorly understood. Here we show that during aging the main lipase of triacylglycerols, ATGL, significantly declines in gastrocnemius and its downregulation in C2C12 myoblast leads to the accumulation of lipid droplets. Indeed, we observed an increase of oxidative damage to proteins in terms of carbonylation, S-nitrosylation and ubiquitination that is dependent on a defective antioxidant cell response mediated by ATGL-PPARα-PGC-1α. Overall our findings describe a pivotal role for ATGL in the antioxidant/anti-inflammatory response of muscle cells highlighting this lipase as a therapeutic target for fighting the progressive decline in skeletal muscle mass and strength.
Keywords: antioxidants, lipid metabolism, myoblasts, oxidative stress, inflammation, Gerotarget
INTRODUCTION
With the term “sarcopenia” is usually indicated a progressive decline in skeletal muscle mass and strength, a process that occurs physiologically during aging and is responsible for the weakness and compromised locomotion of the elderly [1]. Several factors were indicated to be responsible for the onset of such condition, but no efficient interventions were established for its avoidance. Among them the most stated are: reduction of physical activity, decreased number and increased irregularity of muscle units, lowered anabolic hormones and enhanced cytokine activity [1].
At the molecular level, it has been evidenced that an unbalanced reactive oxygen species (ROS) burst is a hallmark in the processes underlying aging/sarcopenia of skeletal muscle, with increased amount of oxidative damage to lipids, DNA and proteins [2]. However, which of the common molecular redox-sensitive pathways are critical for the oxidative damage remains uncertain. Considerable data pointed out that aged-skeletal muscle becomes unable to activate the antioxidant response pathways to cope with ROS deriving from muscle contraction activity, indicating that redox transcription factors are indispensable for maintaining the integrity of muscles [3, 4].
Recently, we have delineated an antioxidant cellular response aimed at counteracting oxidative/nitrosative stress, a circumstance occurring in several age-related diseases and healthy aging upon shortage of canonical antioxidants, such as glutathione. Indeed, under glutathione withdrawal, the peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PGC-1α) is up-regulated in various tissues including skeletal muscle. PGC-1α enforces the transcription of the redox-sensitive nuclear factor (erythroid-derived 2)-like2 (NFE2L2), which in turn promotes the expression of the antioxidant enzymes such as manganese superoxide dismutase (SOD2) and γ-glutamylcysteine ligase (γ-GCL) [5]. Even though the molecular mechanism through which PGC-1α exerts this effect was not identified, the PGC-1α/NFE2L2 axis is of interest in skeletal muscle function where PGC-1α plays fundamental roles, also related to mitochondrial homeostasis.
Reduction in basal rates of mitochondrial oxidative phosphorylation is another common age-related process concurring to muscle derangements that could be responsible for the increased intramyocellular lipid droplets (IMLDs) accumulation. In particular, immunohistochemical studies carried out on muscle biopsies from young (22 years) and old (73 years) individuals demonstrated that older adults have larger IMLDs, fewer mitochondria and a lower proportion of IMLDs in contact with mitochondria [6]. These modifications are important aspects of the skeletal muscle aging process, which leads to an unbalance of lipid and oxidative metabolism and mitochondrial dysfunctions [7].
In order to be funneled towards the mitochondrial oxidative degradation, fatty acids (FAs) need to be firstly conjugated in triacylglycerols (TAGs) and stored in lipid droplets (LDs), which represent the reservoir of “aerobic” energy. LDs are dynamic organelles responding to energy and lipid homeostasis in a very tight-regulated manner. Therefore, their number and size are dependent on the activity of hydrolytic lipases, which are able to completely disassemble TAGs. Three different types of lipases, often hormonally-regulated, are known, among which the adipose triglyceride lipase (ATGL) catalyzes the first step of the TAGs lipolysis cascade, i.e. the hydrolytic cleavage of TAGs into FAs and diacylglycerols (DAGs). ATGL is predominantly expressed in adipose tissue and present, to a lesser extent, in testis, cardiac and skeletal muscle [8]. In particular, ATGL is exclusively expressed in type I (oxidative) muscle fibers, where it possibly plays an indispensable role in FAs metabolism [9]. In fact, ATGL deletion in mice yielded a phenotype with increased whole body fat mass and neutral lipids accumulating in adipose and non-adipose tissues [10].
FAs liberated by ATGL, besides being used by mitochondria for energy production, have been implicated in lipid signaling mediated by the family of peroxisome proliferator activated receptors (PPARs) [11]. In particular, PPARα-activation induces a negative transcriptional regulation of nuclear transcription factor-kappa B (NF-kB) and activating protein-1 (AP-1) [12], while it stimulates the antioxidant response through increased expression of superoxide dismutase and catalase [13]. Moreover, we demonstrated that, during aging, adipocytes exhibit impaired activation of ATGL and PPARα-mediated lipid signaling pathway that results in the up-regulation of pro-inflammatory cytokines, such as TNFα and IL-6, highlighting a fundamental role of ATGL in counteracting age-related inflammation [14, 15].
On the basis of this knowledge, we hypothesized an involvement of ATGL and PPARα-mediated lipid signaling in skeletal muscle and a possible impairment of such processes during aging. To test this hypothesis, we assessed the expression of established PGC-1α target genes in relation to the aforementioned antioxidant response in skeletal muscle during aging. We showed that a progressive decline of ATGL expression characterizes muscle aging and was accompanied by defects in the antioxidant response. These events were recapitulated in young ATGL-KO mice, indicating that ATGL is essential in orchestrating the FAs-PPARα-PGC-1α antioxidant/anti-inflammatory response.
RESULTS
Oxidative/nitrosative stress and inflammation correlate with ATGL down-regulation and fibers atrophy in skeletal muscle of old mice
The progression of aging is well known to result in reduction of mitochondrial content in skeletal muscle and whole-body muscle mass (sarcopenia) [16]. Next to this, an accumulation of IMLDs has been observed mostly in human type I fibers and in rhesus monkeys during aging [6, 17]. Similar defects in lipid accumulation have been observed in humans suffering from neutral lipid storage disease with myopathy (NLSDM), a rare disorder caused by different mutations in the gene coding for ATGL [18, 19]. Indeed, these patients accumulate large amounts of TAGs in skeletal muscle that confers muscle weakness and skeletal muscle myopathy [20].
Given that the IMLDs metabolism is tightly dependent upon the activity of intracellular lipases, we hypothesised that specific lipases managing TAGs catabolism could be affected also in skeletal muscle of old mice. In particular, we looked at ATGL, which is exclusively expressed in type I fibers of skeletal muscle. These fibers are classified as slow-twitch according to the mode of metabolism (aerobic, phosphorylation) and are characterized by high TAGs storage compared to type II fibers (anaerobic, glycolysis). Figure 1A displays that old mice have ATGL protein level significantly decreased compared to young mice. Moreover, RT-qPCR analysis shows a dramatic reduction of ATGL mRNA (Figure 1B), indicating an affected lipolytic cascade in myofibers.
Aging correlates also with increased oxidative damage in skeletal muscle that contributes to loss of tissue homeostasis [4]. Impairment of redox balance has been demonstrated to induce oxidative modifications of proteins, including carbonylation and ubiquitination [16, 21]. Thus, we measured the extent of protein oxidation and ubiquitination in the total protein lysates. As shown in Figure 1A, a raise in total carbonylated and ubiquitinated proteins is observed in old mice, which exhibit also a higher extent of protein S-nitrosylation (Figure 1A), confirming an imbalance of both oxidative and nitrosative conditions during aging.
Inflammation is another important condition in age-related skeletal muscle degeneration [22]. Moreover, a modulatory action of ATGL on tissue inflammation has been recently reported in cardiac muscle of ATGL-KO mice [23]. In particular, the steatotic heart of these animals shows a prominent up-regulation of inflammatory markers [23]. Accordingly, we found that skeletal muscle of old mice displayed an increase of the pro-inflammatory cytokines such as IL-6 and TNF-α (Figure 1C). From these results it could be suggested that skeletal muscle of old mice is prone to conditions that lead to degeneration of myofibers. Then we analyzed the level of fiber atrophy by measuring the content of Atrogin-1 and Murf-1, E3 ubiquitin ligases that are important regulators of ubiquitin-mediated protein degradation in skeletal muscle [24]. Old mice displayed a significant increase of Atrogin-1 and Murf-1 mRNA levels (Figure 1D), confirming the occurrence of skeletal muscle degenerative program during aging.
Overall the results so far obtained, while in part confirmatory of the detrimental age-associated processes, outline a prominent decrement of ATGL in old mice. Moreover, it is worth noting that ATGL decrement could be the upstream event responsible for both oxidative/inflammatory condition and IMLDs accumulation. To this aim we next deeply dissected the molecular mechanisms triggered by ATGL downregulation in C2C12 myoblasts.
ATGL downregulation leads to accumulation of inflammatory markers in C2C12 myoblasts and myofibers
To dissect the link between ATGL decrease and inflammation we down-regulated its expression by means of siRNA. C2C12 myoblasts were transfected with a siRNA against ATGL (ATGL(−)) or with a scramble siRNA (scr). Downregulation of ATGL was successfully achieved as both its mRNA and protein content were significantly decreased (Figure 2A and 2B). Moreover, ATGL down-regulation led to the accumulation of LDs (Figure 2C), demonstrating the effective impairment of lipid catabolism in ATGL(−) cells.
ATGL-released FAs control the expression and activity of PPARα that is considered a powerful repressor of inflammatory genes [12] and an activator of antioxidant enzymes (i.e. superoxide dismutase, catalase) [25, 26]. Moreover, we previously demonstrated that upon ATGL down-regulation FAs/PPARα signalling was impaired in visceral adipose tissue and adipocytes during aging [14]. The same experimental conditions also determine an induction of inflammation [14, 15]. Thus, we investigated the level of PPARα and pro-inflammatory genes both in ATGL-down-regulating C2C12 myoblasts and in skeletal muscle during aging. The analysis of PPARα protein level revealed that its expression was significantly dampened in old mice and in ATGL(−) myoblasts (Figure 2D). In line with the anti-inflammatory role of ATGL/FAs/PPARα pathway, ATGL down-regulation in C2C12 myoblasts led to an enhanced expression of pro-inflammatory cytokines as evidenced by increased mRNA levels of IL-6 and TNF-α (Figure 2E). Therefore, on the basis of these data we can suggest that the rise of pro-inflammatory cytokine production, observed during aging, could be at least in part due to the failure of ATGL-FAs-PPARα-mediated signalling pathways.
ATGL downregulation causes an alteration of antioxidants in C2C12 myoblasts and in myofibers
Next we analyzed role of ATGL in modulating oxidative metabolism and antioxidant defence in skeletal muscle. We first monitored the production of ROS/ONOO.− in ATGL(−) cells. Figure 3A shows an augmented percentage of DCF+ cells as consequence of an increased ROS/ONOO.− flux in ATGL(−) with respect to scr cells. ROS/ONOO.− imbalance was accompanied by increased levels of oxidized proteins in terms of ubiquitinated, carbonylated and S-nitrosylated (Figure 3B). These results indicated that ATGL deficiency might be causative of the oxidative stress observed in skeletal muscle during aging. Moreover, we measured the levels of glutathione (GSH), the main intracellular non-enzymatic antioxidant that safeguards protein integrity by impending ROS- and NO-mediated damage [27]. Figure 3C shows that GSH was significantly decreased in ATGL(−) cells as well as in skeletal muscle of old mice.
We previously demonstrated that the disruption of the redox buffer controlled by GSH leads to PGC-1α up-regulation that is directed to potentiate the antioxidant defence through NFE2L2-mediated expression of SOD2 and γ-GCL [5]. PGC-1α is a master controller of cell metabolism and represents a down-stream target of the ATGL-governed lipid signalling [28]. Therefore, we evaluated whether the ATGL decrease results in the impairment of PGC-1α-mediated antioxidant response. As expected a reduction of protein and mRNA levels of PGC-1α were observed in ATGL(−) cells (Figure 3D) as well as in old mice (Figure 3E). Thus, we moved to prove that reduced ATGL-PPARα-PGC-1α signaling pathway leads to defective antioxidant response during aging.
The analysis of the protein and mRNA levels of NFE2L2 demonstrated that it was significantly reduced in ATGL(−) cells (Figure 3D) and in old mice (Figure 3E). We then evaluated whether ATGL-downregulation could inhibit PGC-1α/NFE2L2-governed antioxidant response. The protein (Figure 3D and 3E) and mRNA (Figure 4A and 4B) levels of SOD2 and γ-GCL were significantly decreased in ATGL(−) cells and in old mice, confirming an impairment of ATGL-PPARα-PGC-1α-mediated antioxidant response. To verify whether the binding activity of NFE2L2 complex was modulated by ATGL deficiency, NFE2L2 association with promoter of the mouse GCLC gene, coding for the catalytic subunit of γ-GCL, was assayed. ChIP analysis indicated that NFE2L2 binding activity was decreased in the occupancy of NFE2L2 responsive element in the GCLC promoter upon AGTL down-regulation as well as in old mice (Figure 4C).
In summary, these results highlight the role of ATGL in orchestrating the antioxidant response in skeletal muscle during aging. In particular, ATGL by providing FAs, is able to activate the PPARα-PGC-1α complex, which in turn induces the expression of NFE2L2-mediated antioxidant genes (i.e. SOD2 and γ-GCL), preventing oxidative stress.
Skeletal muscle of young ATGL-KO mice resemble that of aged mice
To confirm the essential role of the lipolytic activity of ATGL in maintaining skeletal muscle redox homeostasis and functionality, we analyzed some of the molecular factors previously observed in the murine model of ATGL-KO. Although the ATGL-KO mice used were young (six weeks), their skeletal muscles showed the same characteristics of old wild-type (WT) mice. In particular, ATGL-KO mice displayed a decrease of PPARα (Figure 5A) that was associated with a powerful induction of pro-inflammatory cytokines (IL-6 and TNF-α) in a similar way to that observed in old mice and in ATGL(−) cells (Figure 5B). Moreover, skeletal muscle of ATGL-KO mice displayed decreased protein (Figure 5A) and mRNA (Figure 5C) levels of PGC-1α, NFE2L2, SOD2 and γ-GCL. This phenomenon was associated with decreased level of GSH (Figure 5D) and accumulation of carbonylated proteins (Figure 5E). Next, we evaluated the levels of atrophy markers also in ATGL-KO young mice and found a significant increase of their expression (Figure 5F) respect to WT mice as it happens in aged mice, confirming that ATGL deficiency could influence the integrity of skeletal muscle.
All these results demonstrate that the generation of FAs by ATGL provides ligands for functional signaling by the PPARα-PGC-1α complex, which through NFE2L2 is able to activate the antioxidant response and maintain skeletal muscle function and homeostasis. The progressive decrease of ATGL in aged skeletal muscle causes a lipolytic defect that results in massive lipid accumulation, drastic reduction of PPAR-α–regulated gene expression, defective antioxidant response and severe skeletal muscle dysfunction (atrophy).
DISCUSSION
Several data and hypotheses present in literature stated for multifactorial origin of old-associated sarcopenia. However, a well-characterized hallmark of such condition is the presence of IMLDs. In this work, we show how the catabolism of cellular TAGs has a key role in maintaining antioxidant response and functionality of aged skeletal muscle. In particular, this process requires the hydrolytic activity of ATGL. In fact, besides its role in adipose tissue lipolysis, ATGL plays an important role in TAGs metabolism and storage of skeletal muscle [29]. In particular, it has been demonstrated that ATGL is exclusively expressed in type I oxidative muscle fibers, which are characterized by high TAGs content compared to type II fibers, suggesting that this enzyme plays an important role in intramuscular FAs handling [9].
Aged skeletal muscle undergoes a process of structural and functional remodelling leading to loss of muscle mass and force (sarcopenia) [30]. This phenomenon is accompanied by an accumulation of oxidative damage that may contribute to loss of tissue homeostasis and atrophy [31]. The cause of this increased oxidative damage is unclear, but it might be assumed that during aging the ability of skeletal muscle to respond to ROS imbalance is very attenuated. Moreover, previous investigations indicated that intermuscular fat increases with advancing age [32], and magnetic resonance spectroscopy [33] and ultrastructural [6] studies showed that elderly subjects have greater IMLDs accumulated in type I fibers. Haemmerle and colleagues have shown that progressive lipids accumulation and myocardial fibrosis in heart of ATGL-KO mice was accompanied by left ventricular hypertrophy and impaired left ventricular systolic function [10], suggesting that the correct enzymatic activity of ATGL is a limiting condition for the cardiac muscle functionality and homeostasis. Thus, the identification of potential target/signalling pathway could help in alleviating aging-dependent oxidative damage and atrophy.
Our findings delineate an important concept in aged skeletal muscle physiology, underlying that ATGL-mediated lipolysis is essential for the maintenance of PPARα-PGC-1α-mediated antioxidant response and for skeletal muscle function and homeostasis. In particular, we initially found a progressive decrease of ATGL expression in skeletal muscle of C57BL/6 old mice. This decline causes lipolytic defects that result in: i) lipid accumulation, ii) drastic increase of oxidatively damaged proteins, and iii) severe decrease of antioxidant response. A similar phenotype is observed also in gastrocnemius/soleus of young ATGL-KO mice as well as in ATGL-deprived C2C12 myoblasts, indicating that this enzyme is responsible for TAG turnover and FAs-PPARα-antioxidant target genes expression also in skeletal muscle. In fact, ATGL-released FAs play an important role in the regulation of oxidative metabolism. Actually, the hydrolytic activity of ATGL generates lipolytic products, which can behave as ligand or ligand precursors (e.g. FAs, acyl-CoA and FAs-derived compounds) for functional signaling by the PPARα–PGC-1α complex of mitochondrial biogenesis, OXPHOS complexes and antioxidant response [11].
In our work, we substantiated that progressive decline or absence of ATGL leads to an impairment of lipid signaling and downstream antioxidant defense, determining an increase of oxidative/nitrosative stress. We have previously demonstrated that during the progressive decline of GSH, occurring with normal aging, the activation of PGC-1α/NFE2L2 pathway stimulates a sort of adaptive response that buffers the potential harmful effect of ROS/RNS, resulting in mild oxidative stress and protection against cell death [5, 34]. In line with this, the lack of ATGL-mediated FAs/PPARα signaling results in decreased expression of PGC-1α. Consistent with its established roles in skeletal muscle, mitochondrial biogenesis, substrate oxidation and prevention of oxidative stress [35], low skeletal muscle PGC-1α levels may contribute to accumulation of ROS/RNS and impaired antioxidant response [36]. Here we show that, these events are accompanied by an accumulation of damaged proteins that are eliminated by ubiquitin-proteasome system. Moreover, the loss of proteins and organelles likely result in the degeneration and atrophy of aged and ATGL-KO myofibers. In fact, we show an up-regulation of the muscle-specific atrophy-related ubiquitin ligases Atrogin-1/MAFbx and Murf-1 that accelerates protein turnover via the ubiquitin-proteasome system.
The important role of PGC-1α in mechanism controlling muscle mass loss has been recently reported. The maintenance of high levels of PGC-1α during catabolic conditions spares muscle mass upon aging and sarcopenia [37-39]. The positive action on muscle mass of this cofactor is due to the inhibition of ubiquitin-proteasome degradation. PGC-1α reduces protein breakdown by inhibiting the transcriptional activity of FoxO3 and NF-κB [40]. Thus, in our work the decrease of this co-activator could unlock the functionality of proteolytic systems by activating the action of the pro-atrophy transcription factors.
In this context, preliminary results from us pointed out that ATGL decrement is effective also at late stages of myoblasts differentiation and it could be dampened by treatment with MG132, a proteasome inhibitor, implying a prominent role of this degradation pathway in controlling ATGL turnover (personal communication). This is in line with data present in literature indicating that ATGL protein expression was strongly stabilized by the same proteasome inhibitor [41].
FAs can regulate cell metabolism and inflammation. The lipid-sensing PPARs transcription factors link lipid metabolism to inflammatory processes. In particular, PPARα signaling is an important key player not only in energy metabolism, but also in inflammatory response [42]. In fact, it has been demonstrated that PPARα functions like a repressor of inflammation [43]. An induction of FAs/PPARα-mediated inflammation has been observed during ATGL deficiency in visceral adipose tissue and adipocytes [14, 15]. Moreover, PPARα-KO mice show a prolonged inflammatory response [44]. The anti-inflammatory role of PPARα in skeletal muscle is strongly supported by the analysis of PPARα levels in old mice and young ATGL-KO mice, which harbored a significant reduction of PPARα levels concomitant to the production of inflammatory mediators. Our findings suggest that the aged skeletal muscle is a smoldering inflammatory state driven by cytokines, protein catabolism and oxidative stress, which may interfere with muscle contraction and induce ultimately to sarcopenia.
Actually, individuals affected by NLSDM showed altered lipid accumulation in tissues including skeletal muscle, with variable clinical symptoms, except myopathy [20]. Most NLSDM mutations lead to a truncated form of ATGL that, though lacking the C-terminal region (where the LD-binding domain is located), is not affected in lipolytic activity.
Here we give proof of the importance of the FAs generation by ATGL in skeletal muscle during aging. We propose that the progressive decline of ATGL in aged skeletal muscle could be the primum movens for oxidative/inflammatory conditions. In fact, the massive IMLDs accumulation, accompanied by a reduction of their oxidation, could be responsible for inflammation and oxidative damage that, at the end, would lead to skeletal muscle atrophy. These findings reveal how ATGL, through the promotion of lipid signaling, functions as anti-oxidant/anti-inflammatory-protein via the induction of FAs/PPARα-PGC-1α-mediated pathway in young skeletal muscle and indicate that the alteration of this signaling axis is a fundamental event in age-associated skeletal muscle dysfunction.
MATERIALS AND METHODS
Animals
We conducted all mouse experimentations in accordance with accepted standard of humane animal care and with the approval by relevant national (Ministry of Welfare) and local (Institutional Animal Care and Use Committee, Tor Vergata University, Rome, Italy) committees. C57BL/6 mice were purchased from Harlan Laboratories Srl (Urbino, Italy). Male and female ATGL-KO mice, and the corresponding WT mice, were generously provided by Prof. R Zechner and Dr. G Heammerle (Institute of Molecular Biosciences, University of Graz, Graz, Austria). ATGL-KO mice were generated by targeted homologous recombination and were backcrossed on a C57BL/6 genetic background [10]. 12- and 80-weeks-old mice were considered as young and old mice, respectively. Mice were fed ad libitum with standard pellet diet and free access to water. Before sacrifice mice were subjected to fasting for seven hours. Mice were killed by cervical dislocation, gastrocnemius/soleus muscle was explanted immediately, frozen on dry ice and stored −80¼C.
Cell cultures
The murine skeletal muscle C2C12 cells were obtained from the European Collection of Cell Cultures (Salisbury, UK). C2C12 myoblasts were cultured in growth medium composed of Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin/streptomycin and 2 mM glutamine (Lonza Sales, Basel, Switzerland) and maintained at 37°C in an atmosphere of 5% CO2 in air.
Transfection
24 h after plating, C2C12 myoblasts were transfected with a siRNA duplex directed against the following mouse ATGL (SASI_Mm01_00082035) target sequence (ATGL(−) cells). Transfection with a scramble siRNA duplex (scr), with no homology to other mouse mRNA, was used as control. Cells were transfected by electroporation as described previously [45] and transfection efficiency of siRNA was evaluated by co-transfecting siRNAs with nonspecific rhodamine-conjugated oligonucleotides. Only experiments that gave transfection efficiency of 80% were considered. Twenty-four hours after transfection (day 0), differentiation was induced.
Western blot analysis
Cell pellets were resuspended in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 12 mM deoxycholic acid, 0.5% Nonidet P-40 and protease inhibitors). Protein samples were used for SDS-PAGE followed by Western blotting as previously described [46]. Nitrocellulose membranes were stained with primary antibodies against Tubulin (1:1000), PGC-1α (1:500), SOD2 (1:2000), NFE2L2 (1:1000), ATGL (1:1000), Ub (1:1000) and PPARα (1:1000). Afterward, the membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody, and immunoreactive bands were detected by a Fluorchem Imaging System upon staining with ECL Select Western Blotting Detection Reagent (GE Healthcare, Pittsburgh, PA, USA; RPN2235). Immunoblots reported in the figures are representative of at least four experiments that gave similar results. Tubulin was used as the loading control.
Determination of protein carbonylation
Carbonylated proteins were detected using the OxyBlot Kit (Millipore, S7150) as previously described [47]. Briefly, 20 μg of total proteins were reacted with 2,4 dinitrophenylhydrazine (DNP) for 15 min at 25¼C. Samples were resolved on 10% SDS-polyacrylamide gels and DNP-derivatized proteins were identified by Western blot analysis using an anti-DNP antibody and an appropriate horseradish peroxidase-conjugated secondary antibody.
RT-pPCR analysis
Total RNA was extracted using TRI Reagent (Sigma-Aldrich) and used for retro-transcription as previously described [48]. Three micrograms of RNA was used for retro-transcription with M-MLV (Promega). qPCR was performed in triplicates by using validated qPCR primers (BLAST), Ex TAq qPCR Premix and the Real-Time PCR LightCycler II (Roche Diagnostics, Indianapolis, IN, USA). mRNA levels were normalized to RPL mRNA, and the relative mRNA levels were determined by using the 2−ΔΔCt method. The primer sequences are listed in Table 1.
Table 1. List of primers used for RT-qPCR and ChIP analysis.
Genes | Sequences |
---|---|
ATGL FW ATGL RV |
5′-CAACGCCACTCACATCTAC-3′ 5′-GGACACCTCAATAATGTTG-3′ |
Atrogin-1 FW Atrogin-1 RV |
5′-GCGACCTTCCCCAACGCCTG-3′ 5′-GGCGACCGGGACAAGAGTGG-3′ |
gclc FW gclc RV |
5′-GCGAGGTTTCTGCTTAGTCA-3′ 5′-ACAATGACTAAGCAGAAACCTCG-3′ |
g-GCL FW g-GCL RV |
5′-CGCACAGCGAGGAGCTTCGG-3′ 5′-CTCCACTGCATGGGACATGGTGC-3′ |
IL-6 FW IL-6 RV |
5′-CTCTGCAAGAGACTTCCATCCA-3′ 5′-GACAGGTCTGTTGGGAGTGG-3′ |
Murf-1 FW Murf-1 RV |
5′-AGGGGCTACCTTCCTCTAAGTG-3′ 5′-TCTTCCCCAGCTGGCAGCCC-3′ |
NFE2L2 FW NFE2L2 RV |
5′-TCCGCCAGCTACTCCCAGGTTG-3′ 5′-TGGGCCTGATGAGGGGCAGTG-3′ |
PGC-1α FW PGC-1α RV |
5′-ACTGCAGGCCTAACTCCTCCCAC-3′ 5′-CCCTCTTGGTTGGCGGTGGC-3′ |
PPARα FW PPARα RV |
5′-TGCAGGTCATCAAGAAGAC-3′ 5′-TGTGCAAATCCCTGCTCTCC-3′ |
RPL FW RPL RV |
5′-GTACGACCACCACCTTCCGGC-3′ 5′-ATGGCGGAGGGGCAGGTTCTG-3′ |
SOD2 FW SOD2 RV |
5′-GTGTCTGTGGGAGTCCAAGG-3′ 5′-AGCGGAATAAGGCCTGTTGT-3′ |
TNFα FW TNFα RV |
5′-ATGGCCTCCCTCTCATCAGT-3′ 5′-CTTGGTGGTTTGCTACGACG-3′ |
Evaluation of ROS content
ROS were detected by cytofluorimetric analysis after incubation for 30 min at 37¼C with 50 μM H2DCF-DA as previously reported [49]. The fluorescence intensity of 10.000 cells from each samples were analyzed by FACScalibur instrument (Beckton-Dickinson, San Jose, CA, USA). Data were analyzed using the WinMDI 2.8 software (Scripps Research Institute, La Jolla, CA, USA).
Chromatin immunoprecipitation assay (ChIP)
ChIP was carried out as previously described [5]. Briefly, after cross-linking of nuclei extracted from C2C12 cells were fragmented by ultrasonication using 4×15 pulse (output 10%, duty 30%). Samples were pre-cleared with pre-adsorbed salmon sperm Protein G agarose beads (1 h, 4°C), and overnight immunoprecipitation using anti-NFE2L2 or control IgG antibody was carried out. After de-cross-linking (1% sodium dodecyl sulfate at 65°C for 3 h), qPCR was used to quantify the promoter binding with 30 cycles total (95°C, 1 s; 60°C, 30 s; 72°C, 60 s). Results are expressed as percentage of Input (1%) values. The primers used are reported in Table 1.
Biotin switch assay
Biotin switch assay was performed as previously described [50]. Briefly, proteins were subjected to S-NO derivatization by incubation in the presence of ascorbate, which reduces S-NO groups. The same sample incubated in the presence of biotin without ascorbate was used as negative control. After protein separation by non-reducing SDS-PAGE and Western blot, biotinylated proteins were detected by incubation of nitrocellulose membrane with HRP-conjugated streptavidin (1:1000).
Protein concentration was determined by the method of Lowry et al. [51].
Determination of GSH
Intracellular GSH level was measured by HPLC as previously described [52].
Lipid assays
TAGs were detected by incubation with 0.25 mg/ml fluorescent Nile Red and staining was microscopically analysed.
Statistical analysis
The results are presented as means ± S.D. Statistical evaluation was conducted by ANOVA, followed by the post-Student-Newman-Keuls test. Differences were considered to be significant at p < 0.05.
Acknowledgments
This work was partially supported by grants from MIUR-PRIN (20125S38FA_002), Ministero della Salute (GR-2011-02348047) and Italian Association for Cancer Research (AIRC -IG 15403).
Footnotes
CONFLICTS OF INTEREST
The authors have no conflict of interests to declare.
REFERENCES
- 1.Peterson CM, Johannsen DL, Ravussin E. Skeletal muscle mitochondria and aging: a review. J Aging Res. 2012;2012:194821. doi: 10.1155/2012/194821. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Vasilaki A, Mansouri A, Van Remmen H, van der Meulen JH, Larkin L, Richardson AG, McArdle A, Faulkner JA, Jackson MJ. Free radical generation by skeletal muscle of adult and old mice: effect of contractile activity. Aging cell. 2006;5:109–117. doi: 10.1111/j.1474-9726.2006.00198.x. [DOI] [PubMed] [Google Scholar]
- 3.Jackson MJ, McArdle A. Age-related changes in skeletal muscle reactive oxygen species generation and adaptive responses to reactive oxygen species. The Journal of physiology. 2011;589:2139–2145. doi: 10.1113/jphysiol.2011.206623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Jackson MJ. Redox regulation of muscle adaptations to contractile activity and aging. Journal of applied physiology. 2015;119:163–171. doi: 10.1152/japplphysiol.00760.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Aquilano K, Baldelli S, Pagliei B, Cannata SM, Rotilio G, Ciriolo MR. p53 orchestrates the PGC-1alpha-mediated antioxidant response upon mild redox and metabolic imbalance. Antioxid Redox Signal. 2013;18:386–399. doi: 10.1089/ars.2012.4615. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Crane JD, Devries MC, Safdar A, Hamadeh MJ, Tarnopolsky MA. The effect of aging on human skeletal muscle mitochondrial and intramyocellular lipid ultrastructure. The journals of gerontology Series A, Biological sciences and medical sciences. 2010;65:119–128. doi: 10.1093/gerona/glp179. [DOI] [PubMed] [Google Scholar]
- 7.Turcotte LP, Fisher JS. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Physical therapy. 2008;88:1279–1296. doi: 10.2522/ptj.20080018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, Zechner R. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science. 2004;306:1383–1386. doi: 10.1126/science.1100747. [DOI] [PubMed] [Google Scholar]
- 9.Jocken JW, Smit E, Goossens GH, Essers YP, van Baak MA, Mensink M, Saris WH, Blaak EE. Adipose triglyceride lipase (ATGL) expression in human skeletal muscle is type I (oxidative) fiber specific. Histochem Cell Biol. 2008;129:535–538. doi: 10.1007/s00418-008-0386-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 2006;312:734–737. doi: 10.1126/science.1123965. [DOI] [PubMed] [Google Scholar]
- 11.Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, Schreiber R, Eichmann T, Kolb D, et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med. 2011;17:1076–1085. doi: 10.1038/nm.2439. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. The Journal of biological chemistry. 1999;274:32048–32054. doi: 10.1074/jbc.274.45.32048. [DOI] [PubMed] [Google Scholar]
- 13.Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. The Journal of biological chemistry. 1998;273:32833–32841. doi: 10.1074/jbc.273.49.32833. [DOI] [PubMed] [Google Scholar]
- 14.Lettieri Barbato D, Aquilano K, Baldelli S, Cannata SM, Bernardini S, Rotilio G, Ciriolo MR. Proline oxidase-adipose triglyceride lipase pathway restrains adipose cell death and tissue inflammation. Cell Death Differ. 2014;21:113–123. doi: 10.1038/cdd.2013.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Lettieri Barbato D, Tatulli G, Aquilano K, Ciriolo MR. Inhibition of age-related cytokines production by ATGL: a mechanism linked to the anti-inflammatory effect of resveratrol. Mediators Inflamm. 2014;2014:917698. doi: 10.1155/2014/917698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Demontis F, Piccirillo R, Goldberg AL, Perrimon N. Mechanisms of skeletal muscle aging: insights from Drosophila and mammalian models. Disease models & mechanisms. 2013;6:1339–1352. doi: 10.1242/dmm.012559. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Pugh TD, Conklin MW, Evans TD, Polewski MA, Barbian HJ, Pass R, Anderson BD, Colman RJ, Eliceiri KW, Keely PJ, Weindruch R, Beasley TM, Anderson RM. A shift in energy metabolism anticipates the onset of sarcopenia in rhesus monkeys. Aging Cell. 2013;12:672–681. doi: 10.1111/acel.12091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R, Lass A. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. Journal of lipid research. 2009;50:3–21. doi: 10.1194/jlr.R800031-JLR200. [DOI] [PubMed] [Google Scholar]
- 19.Fischer J, Lefevre C, Morava E, Mussini JM, Laforet P, Negre-Salvayre A, Lathrop M, Salvayre R. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nature genetics. 2007;39:28–30. doi: 10.1038/ng1951. [DOI] [PubMed] [Google Scholar]
- 20.Schweiger M, Lass A, Zimmermann R, Eichmann TO, Zechner R. Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. Am J Physiol Endocrinol Metab. 2009;297:E289–296. doi: 10.1152/ajpendo.00099.2009. [DOI] [PubMed] [Google Scholar]
- 21.Barreiro E, Hussain SN. Protein carbonylation in skeletal muscles: impact on function. Antioxidants & redox signaling. 2010;12:417–429. doi: 10.1089/ars.2009.2808. [DOI] [PubMed] [Google Scholar]
- 22.Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. International journal of molecular sciences. 2010;11:1509–1526. doi: 10.3390/ijms11041509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Schrammel A, Mussbacher M, Winkler S, Haemmerle G, Stessel H, Wolkart G, Zechner R, Mayer B. Cardiac oxidative stress in a mouse model of neutral lipid storage disease. Biochim Biophys Acta. 2013;1831:1600–1608. doi: 10.1016/j.bbalip.2013.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Gumucio JP, Mendias CL. Atrogin-1, MuRF-1, and sarcopenia. Endocrine. 2013;43:12–21. doi: 10.1007/s12020-012-9751-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Berger J, Moller DE. The mechanisms of action of PPARs. Annual review of medicine. 2002;53:409–435. doi: 10.1146/annurev.med.53.082901.104018. [DOI] [PubMed] [Google Scholar]
- 26.Inoue I, Noji S, Awata T, Takahashi K, Nakajima T, Sonoda M, Komoda T, Katayama S. Bezafibrate has an antioxidant effect: peroxisome proliferator-activated receptor alpha is associated with Cu2+, Zn2+-superoxide dismutase in the liver. Life sciences. 1998;63:135–144. doi: 10.1016/s0024-3205(98)00249-5. [DOI] [PubMed] [Google Scholar]
- 27.Aquilano K, Baldelli S, Ciriolo MR. Glutathione: new roles in redox signaling for an old antioxidant. Frontiers in pharmacology. 2014;5:196. doi: 10.3389/fphar.2014.00196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Khan SA, Sathyanarayan A, Mashek MT, Ong KT, Wollaston-Hayden EE, Mashek DG. ATGL-catalyzed lipolysis regulates SIRT1 to control PGC-1alpha/PPAR-alpha signaling. Diabetes. 2015;64:418–426. doi: 10.2337/db14-0325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Yao-Borengasser A, Varma V, Coker RH, Ranganathan G, Phanavanh B, Rasouli N, Kern PA. Adipose triglyceride lipase expression in human adipose tissue and muscle. Role in insulin resistance and response to training and pioglitazone. Metabolism. 2011;60:1012–1020. doi: 10.1016/j.metabol.2010.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Budui SL, Rossi AP, Zamboni M. The pathogenetic bases of sarcopenia. Clin Cases Miner Bone Metab. 2015;12:22–26. doi: 10.11138/ccmbm/2015.12.1.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010;91:1123S–1127S. doi: 10.3945/ajcn.2010.28608A. [DOI] [PubMed] [Google Scholar]
- 32.Johannsen DL, Conley KE, Bajpeyi S, Punyanitya M, Gallagher D, Zhang Z, Covington J, Smith SR, Ravussin E. Ectopic lipid accumulation and reduced glucose tolerance in elderly adults are accompanied by altered skeletal muscle mitochondrial activity. J Clin Endocrinol Metab. 2012;97:242–250. doi: 10.1210/jc.2011-1798. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Cree MG, Newcomer BR, Katsanos CS, Sheffield-Moore M, Chinkes D, Aarsland A, Urban R, Wolfe RR. Intramuscular and liver triglycerides are increased in the elderly. J Clin Endocrinol Metab. 2004;89:3864–3871. doi: 10.1210/jc.2003-031986. [DOI] [PubMed] [Google Scholar]
- 34.Baldelli S, Aquilano K, Ciriolo MR. Punctum on two different transcription factors regulated by PGC-1alpha: nuclear factor erythroid-derived 2-like 2 and nuclear respiratory factor 2. Biochim Biophys Acta. 2013;1830:4137–4146. doi: 10.1016/j.bbagen.2013.04.006. [DOI] [PubMed] [Google Scholar]
- 35.Dillon LM, Rebelo AP, Moraes CT. The role of PGC-1 coactivators in aging skeletal muscle and heart. IUBMB Life. 2012;64:231–241. doi: 10.1002/iub.608. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Lettieri Barbato D, Baldelli S, Pagliei B, Aquilano K, Ciriolo MR. Caloric Restriction and the Nutrient-Sensing PGC-1alpha in Mitochondrial Homeostasis: New Perspectives in Neurodegeneration. Int J Cell Biol. 2012;2012:759583. doi: 10.1155/2012/759583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Geng T, Li P, Yin X, Yan Z. PGC-1alpha promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac cachexia in mice. Am J Pathol. 2011;178:1738–1748. doi: 10.1016/j.ajpath.2011.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, Spiegelman BM. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A. 2006;103:16260–16265. doi: 10.1073/pnas.0607795103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT. Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A. 2009;106:20405–20410. doi: 10.1073/pnas.0911570106. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 40.Brault JJ, Jespersen JG, Goldberg AL. Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J Biol Chem. 2010;285:19460–19471. doi: 10.1074/jbc.M110.113092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Olzmann JA, Richter CM, Kopito RR. Spatial regulation of UBXD8 and p97/VCP controls ATGL-mediated lipid droplet turnover. Proc Natl Acad Sci U S A. 2013;110:1345–1350. doi: 10.1073/pnas.1213738110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta. 2007;1771:972–982. doi: 10.1016/j.bbalip.2007.04.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394–402. doi: 10.1161/01.res.85.5.394. [DOI] [PubMed] [Google Scholar]
- 44.Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Muia C, Crisafulli C, Caputi AP. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol. 2006;79:999–1010. doi: 10.1189/jlb.0605341. [DOI] [PubMed] [Google Scholar]
- 45.Aquilano K, Baldelli S, Ciriolo MR. Nuclear recruitment of neuronal nitric-oxide synthase by alpha-syntrophin is crucial for the induction of mitochondrial biogenesis. J Biol Chem. 2014;289:365–378. doi: 10.1074/jbc.M113.506733. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Baldelli S, Aquilano K, Rotilio G, Ciriolo MR. Neuronal nitric oxide synthase interacts with Sp1 through the PDZ domain inhibiting Sp1-mediated copper-zinc superoxide dismutase expression. Int J Biochem Cell Biol. 2011;43:163–169. doi: 10.1016/j.biocel.2010.10.016. [DOI] [PubMed] [Google Scholar]
- 47.Baldelli S, Aquilano K, Ciriolo MR. PGC-1alpha buffers ROS-mediated removal of mitochondria during myogenesis. Cell Death Dis. 2014;5:e1515. doi: 10.1038/cddis.2014.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Pagliei B, Aquilano K, Baldelli S, Ciriolo MR. Garlic-derived diallyl disulfide modulates peroxisome proliferator activated receptor gamma co-activator 1 alpha in neuroblastoma cells. Biochem Pharmacol. 2013;85:335–344. doi: 10.1016/j.bcp.2012.11.007. [DOI] [PubMed] [Google Scholar]
- 49.Desideri E, Vegliante R, Cardaci S, Nepravishta R, Paci M, Ciriolo MR. MAPK14/p38alpha-dependent modulation of glucose metabolism affects ROS levels and autophagy during starvation. Autophagy. 2014;10:1652–1665. doi: 10.4161/auto.29456. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Aquilano K, Baldelli S, Cardaci S, Rotilio G, Ciriolo MR. Nitric oxide is the primary mediator of cytotoxicity induced by GSH depletion in neuronal cells. J Cell Sci. 2011;124:1043–1054. doi: 10.1242/jcs.077149. [DOI] [PubMed] [Google Scholar]
- 51.Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275. [PubMed] [Google Scholar]
- 52.Desideri E, Filomeni G, Ciriolo MR. Glutathione participates in the modulation of starvation-induced autophagy in carcinoma cells. Autophagy. 2012;8:1769–1781. doi: 10.4161/auto.22037. [DOI] [PMC free article] [PubMed] [Google Scholar]